Literature DB >> 33978582

Frailty and Sarcopenia in Patients Pre- and Post-Liver Transplant.

Yedidya Saiman1, Marina Serper2.   

Abstract

Greater than half of patients with decompensated liver disease suffer from frailty and/or sarcopenia, which can lead to increased pre- and post-liver transplant morbidity and mortality. Although frailty and sarcopenia can impact patients with end-stage liver disease in similar ways, they are unique clinical entities with differing underlying etiologies. Early assessment and identification of frailty and sarcopenia in patients is critical to guide clinical decision-making regarding transplantation and to implement nutritional and exercise-based treatment regiments. Nonetheless, accurate diagnosis and, in particular, predicting patients that will develop frailty and/or sarcopenia remains challenging, and the success of clinical interventions is limited.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Frailty; Liver transplantation; Malnutrition; Sarcopenia

Year:  2020        PMID: 33978582     DOI: 10.1016/j.cld.2020.08.004

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Should sarcopenia be an additional factor enough to affect liver transplant decision-making?

Authors:  Kang He; Qiang Xia
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

2.  Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list.

Authors:  Ezequiel Mauro; Juan Manuel Diaz; Lucrecia Garcia-Olveira; Juan Carlos Spina; Lorena Savluk; Fernanda Zalazar; Julia Saidman; Martin De Santibañes; Juan Pekolj; Eduardo De Santibañes; Gonzalo Crespo; Juan G Abraldes; Adrían Gadano
Journal:  Hepatol Commun       Date:  2022-03-03

3.  Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis.

Authors:  Koji Murata; Kosuke Kaji; Norihisa Nishimura; Masahide Enomoto; Yuki Fujimoto; Soichi Takeda; Yuki Tsuji; Yukihisa Fujinaga; Hiroaki Takaya; Hideto Kawaratani; Tadashi Namisaki; Takemi Akahane; Hitoshi Yoshiji
Journal:  Int J Mol Med       Date:  2022-06-10       Impact factor: 5.314

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.